Aniracetam
Nootropics
View productThis site is an educational resource for research compounds. We do not endorse human consumption of any compound. We rank every vendor on the same public methodology, and we earn a commission on purchases through some of our links. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

Also known as: ICS 205-930, SDZ ICS 930, Navoban, Novaban, Tropisetron hydrochloride, Tropiestron (market misspelling)
Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). It has never been approved by the FDA, which is why American research groups describe it as a drug already approved for clinical use outside the United States (PMID: 15927799).
Tropisetron is a potent and selective serotonin 5-HT3 receptor antagonist, the property behind its antiemetic license, blocking 5-HT3 receptors on peripheral neurones involved in the emetic reflex with possible additional action at 5-HT3 receptors in the area postrema (PMID: 8363…
Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). It has never been approved by the FDA, which is why American research groups describe it as a drug already approved for clinical use outside the United States (PMID: 15927799). Material sold on the research chemical market as Tropiestron is a misspelling of the same drug. Interest beyond nausea comes from a second property. Tropisetron is a partial agonist at the alpha7 nicotinic acetylcholine receptor. Oocyte electrophysiology traced that activity to the tropane portion of the molecule and showed that the indole portion mainly determines potency and subtype selectivity (PMID: 15781147). Positron emission tomography with the alpha7 radioligand CHIBA-1001 showed that a single oral dose lowered radioligand distribution volume in the human brain while ondansetron did not, so alpha7 engagement happens at ordinary clinical exposure (PMID: 23430308). A separate drug screen also found that it binds the ectodomain of amyloid precursor protein (PMID: 24389031). Preclinical work follows that thread. Tropisetron improved deficient inhibitory processing of the auditory evoked potential in DBA/2 mice, an effect blocked by the alpha7 antagonist methyllycaconitine (PMID: 16136299); improved phencyclidine-induced cognitive deficits in mice, again blocked by methyllycaconitine (PMID: 17094961); and improved apomorphine-disrupted prepulse inhibition in Wistar rats (PMID: 20673759). In J20 transgenic mice it improved memory and the sAPPalpha to amyloid-beta ratio more than memantine or donepezil at comparable doses (PMID: 24389031). Outside the brain it reduced collagen synthesis in human dermal fibroblasts and reduced established dermal fibrosis in a bleomycin mouse model of scleroderma through alpha7 receptors (PMID: 23440693). Human trials outside emesis are small but real. Three randomized controlled trials, each with 40 patients with schizophrenia stabilized on risperidone, reported improved P50 auditory gating and cognition after 10 days (PMID: 22952075), improved P50 gating and sustained visual attention after 8 weeks (PMID: 20573264), and improved negative symptoms after 8 weeks (PMID: 23515583). In fibromyalgia, a randomized double-blind placebo-controlled multicenter trial in 21 women reported a larger fall in pain scores than placebo, which reached significance on a secondary body diagram score and not on the primary visual analog scale (PMID: 15370724). Pharmacokinetics are dominated by CYP2D6. In 18 healthy volunteers, oral bioavailability ranged from 0.27 to 0.99 and correlated inversely with CYP2D6 activity measured by the sparteine metabolic ratio, with a half-life near 5.7 h (PMID: 11736884). Poor metabolisers get higher exposure with more headache and constipation, ultrarapid metabolisers get less antiemetic effect, and this relationship is now covered by a Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and 5-HT3 receptor antagonists (PMID: 8363993, PMID: 12065557, PMID: 41979467). Every use outside the licensed antiemetic indication is investigational.
IUPAC Name
Not yet available
CAS Number
89565-68-4 (free base); 105826-92-4 (hydrochloride)
Molecular Formula
C17H20N2O2
Molecular Mass
284.35 g/mol (free base)
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Sourced and mechanism-based: metabolism depends on CYP2D6, so ultrarapid metabolisers get lower exposure and reduced antiemetic effect while poor metabolisers get higher exposure and more adverse effects (PMID: 12065557, PMID: 11736884), the basis of the Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and 5-HT3 receptor antagonists (PMID: 41979467). Constipation and other gastrointestinal effects make pre-existing bowel obstruction or severe constipation a mechanism-based concern (PMID: 8363993). Use outside a licensed antiemetic indication is investigational and unsupervised use carries no evidence base.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$89.99
—
1
1
capsule
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
![]() |
Tropisetron capsules (60) | capsule | 60 capsules● In Stock | $89.99BEST | — | — |
Tracking since Sep 7, 2026 · 1 data point
How we score these vendors
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Albuterol, called salbutamol outside the United States, is a beta-2 adrenergic agonist and a standard asthma medicine worldwide.
Clascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S.
Finasteride is an orally-active selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgenic driver of both benign prostatic hyperplasia (BPH) and androgenetic alopecia (male-pattern hair loss).
Galantamine is an alkaloid first isolated from snowdrop plants that blocks the enzyme acetylcholinesterase, and it has been an FDA-approved prescription drug for mild to moderate dementia of the Alzheimer's type since 2001 (PMID: 29669164, PMID: 15137996; Drugs@FDA NDA 021169).
Meldonium, sold as Mildronate, was developed at the Latvian Institute of Organic Synthesis (PMID: 12242052) and is a licensed cardiovascular medicine in Latvia and a number of eastern European and post-Soviet countries.
Mirabegron is an approved prescription drug, not a research chemical.
View Full Dosage Guide →
Protocols, calculator & safety for Tropisetron
0 PubMed results
Data Completeness
63%COA Verification
0
Verified COAs
1
Vendors w/ COA
Latest test: 9/16/2026
Half-Life
About 5.7 h after a single 5 mg oral capsule and 5.6 h after 2 mg intravenously in 18 healthy volunteers; oral bioavailability averaged 0.60 with a range of 0.27 to 0.99 and was inversely related to CYP2D6 activity (PMID: 11736884)
Molecular Weight
284.35 g/mol (free base)
Administration
Oral, Intravenous injection
CAS Number
89565-68-4 (free base); 105826-92-4 (hydrochloride)
Trial Phase
Approved (Japan)
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Tropisetron, coded ICS 205-930 during development and marketed as Navoban, is a serotonin 5-HT3 receptor antagonist approved as an antiemetic in Japan and in many other countries outside the United States, with ATC code A04AA03 (KEGG DRUG D02041, D02130). It has never been approved by the FDA, which is why American research groups describe it as a drug already approved for clinical use outside the United States (PMID: 15927799). Material sold on the research chemical market as Tropiestron is a misspelling of the same drug.
Interest beyond nausea comes from a second property. Tropisetron is a partial agonist at the alpha7 nicotinic acetylcholine receptor. Oocyte electrophysiology traced that activity to the tropane portion of the molecule and showed that the indole portion mainly determines potency and subtype selectivity (PMID: 15781147). Positron emission tomography with the alpha7 radioligand CHIBA-1001 showed that a single oral dose lowered radioligand distribution volume in the human brain while ondansetron did not, so alpha7 engagement happens at ordinary clinical exposure (PMID: 23430308). A separate drug screen also found that it binds the ectodomain of amyloid precursor protein (PMID: 24389031).
Preclinical work follows that thread. Tropisetron improved deficient inhibitory processing of the auditory evoked potential in DBA/2 mice, an effect blocked by the alpha7 antagonist methyllycaconitine (PMID: 16136299); improved phencyclidine-induced cognitive deficits in mice, again blocked by methyllycaconitine (PMID: 17094961); and improved apomorphine-disrupted prepulse inhibition in Wistar rats (PMID: 20673759). In J20 transgenic mice it improved memory and the sAPPalpha to amyloid-beta ratio more than memantine or donepezil at comparable doses (PMID: 24389031). Outside the brain it reduced collagen synthesis in human dermal fibroblasts and reduced established dermal fibrosis in a bleomycin mouse model of scleroderma through alpha7 receptors (PMID: 23440693).
Human trials outside emesis are small but real. Three randomized controlled trials, each with 40 patients with schizophrenia stabilized on risperidone, reported improved P50 auditory gating and cognition after 10 days (PMID: 22952075), improved P50 gating and sustained visual attention after 8 weeks (PMID: 20573264), and improved negative symptoms after 8 weeks (PMID: 23515583). In fibromyalgia, a randomized double-blind placebo-controlled multicenter trial in 21 women reported a larger fall in pain scores than placebo, which reached significance on a secondary body diagram score and not on the primary visual analog scale (PMID: 15370724).
Pharmacokinetics are dominated by CYP2D6. In 18 healthy volunteers, oral bioavailability ranged from 0.27 to 0.99 and correlated inversely with CYP2D6 activity measured by the sparteine metabolic ratio, with a half-life near 5.7 h (PMID: 11736884). Poor metabolisers get higher exposure with more headache and constipation, ultrarapid metabolisers get less antiemetic effect, and this relationship is now covered by a Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 genotype and 5-HT3 receptor antagonists (PMID: 8363993, PMID: 12065557, PMID: 41979467). Every use outside the licensed antiemetic indication is investigational.
Tropisetron is available in capsule form.
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
1 of the vendors BodyHackGuide tracks list Tropisetron (1 listing). The lowest listed price BodyHackGuide has recorded for Tropisetron is $89.99. No Tropisetron listing recorded as in stock carries a milligram count, so BodyHackGuide states no price per milligram for Tropisetron.
BodyHackGuide holds 1 third-party certificate record for Tropisetron, from Disguised Alpha. No editor has read any of BodyHackGuide's 1 certificate record for Tropisetron. The laboratory named on BodyHackGuide's Tropisetron certificate record is Freedom Diagnostics Testing, and the test date on it is 30 July 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.
Nootropics
View productNootropics
View productNootropic
View productNootropics
View productAlbuterol, called salbutamol outside the United States, is a beta-2 adrenergic agonist and a standard asthma medicine worldwide.
Clascoterone (brand name Winlevi; development codes CB-03-01 and, for the alopecia formulation, Breezula) is a first-in-class topical androgen receptor (AR) antagonist approved by the U.S.
Finasteride is an orally-active selective type II 5α-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgenic driver of both benign prostatic hyperplasia (BPH) and androgenetic alopecia (male-pattern hair loss).
Galantamine is an alkaloid first isolated from snowdrop plants that blocks the enzyme acetylcholinesterase, and it has been an FDA-approved prescription drug for mild to moderate dementia of the Alzheimer's type since 2001 (PMID: 29669164, PMID: 15137996; Drugs@FDA NDA 021169).
Meldonium, sold as Mildronate, was developed at the Latvian Institute of Organic Synthesis (PMID: 12242052) and is a licensed cardiovascular medicine in Latvia and a number of eastern European and post-Soviet countries.
Mirabegron is an approved prescription drug, not a research chemical.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.